In vitro neurotoxic properties and excitatory aminoacids concentration in the cerebrospinal fluid of amyotrophic lateral sclerosis patients. Relationship with the degree of certainty of disease diagnoses

Acta Neurologica Scandinavica

Volumn 121, Issue 2, 2010, Pages 120-126

  Fiszman, M L ^a,d   Ricart, K C ^a   Latini, A ^b   Rodriguez G ^c   Sica, R E P ^c  

^a Instituto de Investigaciones Farmacologicas   (Argentina)

^b UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^c HOSPITAL RAMOS MEJÍA   (Argentina)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Amyotrophic lateral sclerosis; Cerebrospinal fluid; Excitatory aminoacids; Neuronal cultures; Neurotoxicity; Pathogenesis

Indexed keywords

6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; ASPARTIC ACID; DIZOCILPINE; GLUTAMIC ACID; IONOTROPIC RECEPTOR;

ADULT; AGED; AMINO ACID ANALYSIS; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ARTICLE; CELL VIABILITY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE DURATION; EMBRYO; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; MALE; MOUSE; NERVE CELL CULTURE; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PROTEIN CEREBROSPINAL FLUID LEVEL; SPORADIC AMYOTROPHIC LATERAL SCLEROSIS;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ASPARTIC ACID; CELL SURVIVAL; CELLS, CULTURED; CEREBRAL CORTEX; CEREBROSPINAL FLUID; FEMALE; GLUTAMIC ACID; HUMANS; MALE; MICE; MIDDLE AGED; NEURONS; TIME FACTORS;

EID: 74349126112     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2009.01200.x     Document Type: Article

References (33)

1. Carri MT, Grignaschi G, Bendotti C. Target in ALS: designing multidrug therapies. Trends Pharmacol Sci 2006 27 : 267 273.
2. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988 1 : 623 624.
3. Choi DW, Koh JY, Peters S. Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists. J Neurosci 1988 8 : 185 196.
4. Meldrum B, Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 1990 11 : 379 387.
5. Lipton SA, Rosemberg PA. Excitatory amino acids as a final common pathway for neurological disorders. N Engl J Med 1994 330 : 613 622.
6. Shaw PJ, Forrest V, Ince PG, Richardson JP, Wastell HJ. CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration 1995 4 : 209 216.
7. Sica REP, Dubrovsky AL. Patogenia de la esclerosis lateral amiotrófica. In : Sica REP, Dubrovsky AL, eds. Esclerosis lateral amiotrófica y enfermedades relacionadas. Buenos Aires : Científica Interamericana, 2001 85 96.
8. Plaitakis A, Constantakakis E, Smith J. The neuroexcitotoxic aminoacids glutamate and aspartate are altered in the spinal cord and brain in amyotrophic lateral sclerosis. Ann Neurol 1988 24 : 446 449.
9. Rothstein JD, Tsai G, Kuncl RW et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990 28 : 18 25.
10. Rothstein JD, Kuncl R, Cahudry V et al. Excitatory amino acids in amyotrophic lateral sclerosis: an update. Ann Neurol 1991 30 : 224 225.
11. Urushinati M, Shimohama S, Kihara T et al. Mechanism of selective motor neuronal death after exposure of spinal cord to glutamate: involvement of glutamate-induced nitric oxide in motor neuron toxicity and non motor neuron protection. Ann Neurol 1998 44 : 796 807.
12. Gonzalez Deniselle MC, Garay L, Lopez-Costa JJ et al. Progesterone treatment reduces NADPH-diaphorase/nitric oxide synthase in Wobbler mouse motoneuron disease. Brain Res 2004 1014 : 71 9.
13. Tohgi H, Abe T, Yamazaki K, Murata T, Ishizaki E, Isobe C. Increase in oxidized NO products and reduction in oxidized glutathione in cerebrospinal fluid from patients with sporadic form of amyotrophic lateral sclerosis. Neurosci Lett 1999 260 : 204 206.
14. Kawahara Y, Ito K, Sun H, Aizawa H, Kanazawa I, Kwak S. Glutamate receptors: RNA editing and death of motor neurons. Nature 2004 427 : 801.
15. Tortarolo M, Grignaschi G, Calvaresi N et al. Glutamate AMPA receptors change in motor neurons of SOD1G93A transgenic mice and their inhibition by a noncompetitive antagonist ameliorates the progression of amytrophic lateral sclerosis-like disease. J Neurosci Res 2006 83 : 134 146.
16. Couratier P, Hugon J, Sindou P, Vallat JM, Dumas M. Cell culture evidence for neuronal degeneration in amyotrophic lateral sclerosis being linked to glutamate AMPA/kainate receptors. Lancet 1993 341 : 265 268.
17. Tikka TM, Vartiainen NE, Goldsteins G et al. Minocycline prevents neurotoxicity induced by cerebrospinal fluid from patients with motor neurone disease. Brain 2002 125 : 722 731.
18. Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995 38 : 73 84.
19. Guo G, Lai L, Butchbach MER et al. Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice. Human Molecular Gene 2003 12 : 2519 2532.
20. Kieran D, Hafezparast M, Bohnert S et al. A mutation in dynein recues axonal transport defects and extends the life span of ALS mice. J Cell Biol 2005 169 : 561 567.
21. Terro F, Lesort M, Viader F, Ludolph A, Hugon J. Antioxidant drugs block in vitro the neurotoxicity of CSF of patients with amyotrophic lateral sclerosis. Neuroreport 1996 7 : 1970 1972.
22. Burghes AHM, Butchbach MER. Let all DNA vote: Who are the amyotrophic lateral sclerosis candidates? Neurology 2008 70 : 662 663.
23. Fiszman ML, Ricart KC, Latini A et al. Glutamate concentrations in the cerebrospinal fluid of amyotrophic lateral sclerosis patients. Its relationship with disease progression. Amyotrophic Lateral Scler. 2001 2 (Suppl. 2 135 136.
24. Ricart KC, Sica REP, Latini A et al. Nitric oxide, glutamate and neurotoxic activity in cerebrospinal fluid of patients with sporadic ALS. Amyotrophic Lateral Scler. 2000 2 (Suppl. 2 107 108.
25. Brooks BR, Miller RG, Swash M, Munsat TL. World Federation of Neurology Research Group on Neuromuscular Diseases. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. http://www.wfnals.org/guidelines/1998elescorial/elescorial1998.htm
26. Joseph MH, Marsden CA. Amino acids and small peptides. In : Lim CK, ed. HPLC of small peptides. Oxford : IRL Press, 1986 13 27.
27. Fiszman ML, Borodinsky LN, Neale JH. GABA induces proliferation of immature cerebellar granule cells grown in vitro. Dev Brain Res 1999 115 : 1 8.
28. Ricart KC, Fiszman ML. Hydrogen peroxide-induced neurotoxicity in cultured cortical cells grown in serum-free containing media. Neurochem Res 2001 26 : 801 808.
29. Spreux-Varoquaux O, Bensimon G, Lacomblez L et al. Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J Neurol Sci 2002 193 : 73 8.
30. Perry TL, Kreiger C, Hansen S, Eisen A. Amyotrophic lateral sclerosis: amino acid levels in plasma and cerebrospinal fluid. Ann Neurol 1990 28 : 12 7.
31. Camu W, Billiard M, Baldy-Moulinier M. Fasting plasma and CSF amino acid levels in amyotrophic lateral sclerosis: a subtype analysis. Acta Neurol Scand 1993 88 : 51 5.
32. Spink DC, Swann JW, Snead OC, Waniewski RA, Martin DL. Analysis of aspartate and glutamate in human cerebrospinal fluid by high-performance liquid chromatography with automated precolumn derivatization. Anal Biochem 1986 158 : 79 86.
33. Spink DC, Martin D. Excitatory amino acids in amyotrophic lateral sclerosis. Ann Neurol 1991 29 : 110.